Cargando…

Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy

BACKGROUND: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investigate the prognostic role of lymphopenia, blood prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Abravan, Azadeh, Eide, Hanne Astrid, Helland, Åslaug, Malinen, Eirik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063172/
https://www.ncbi.nlm.nih.gov/pubmed/32181373
http://dx.doi.org/10.1016/j.ctro.2020.02.005
_version_ 1783504662333227008
author Abravan, Azadeh
Eide, Hanne Astrid
Helland, Åslaug
Malinen, Eirik
author_facet Abravan, Azadeh
Eide, Hanne Astrid
Helland, Åslaug
Malinen, Eirik
author_sort Abravan, Azadeh
collection PubMed
description BACKGROUND: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investigate the prognostic role of lymphopenia, blood protein levels, and treatment and patient-related factors. MATERIAL AND METHODS: Sixty-two advanced stage non-small cell lung cancer (NSCLC) patients were retrospectively analyzed. Blood counts were available prior to, during, and after RT (3Gyx10). For each patient, a thoracic volume of interest (VOI) –including thoracic soft tissue and trabecular bone– was obtained by applying a CT window of −500 to 1200 HU in the planning CT. Dose parameters from thoracic VOI and other regions including lungs and vertebrae were calculated. Association between risk of lymphopenia ≥ G3 (lymphocytes at nadir according to CTCAE v4.0) and therapeutic parameters was investigated using Logistic regression. Relationships between overall survival (OS) and RT dose parameters, baseline blood counts and protein levels, and clinical factors were evaluated using Log-rank and Cox models. RESULT: Mean thoracic RT dose (odds ratio [OR] 1.67; p = 0.04), baseline lymphocytes (OR 0.65; p = 0.01), and corticosteroids use (OR 6.07; p = 0.02) were significantly associated with increased risk of lymphopenia ≥ G3 in multivariable analysis. Worse OS was associated with high mean thoracic RT dose, high CRP/Albumin, large tumor volume and corticosteroids use (p < 0.05, univariate analysis), but not with lymphopenia ≥ G3. CRP/Albumin ratio > 0.12 (hazard ratio [HR] 2.28, p = 0.03) and corticosteroid use (HR 2.52, p = 0.01) were independently associated with worse OS. CONCLUSION: High thoracic RT dose gave a higher risk of lymphopenia ≥ G3; hence limiting dose volume to the thorax may be valuable in preventing severe lymphopenia for patients receiving palliative fractionated RT. Still, lymphopenia ≥ G3 was not associated with worse OS. however, high baseline CRP/Albumin was associated with poorer OS and may carry important information as a prognostic factor of OS in advanced NSCLC receiving palliative RT.
format Online
Article
Text
id pubmed-7063172
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70631722020-03-16 Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy Abravan, Azadeh Eide, Hanne Astrid Helland, Åslaug Malinen, Eirik Clin Transl Radiat Oncol Article BACKGROUND: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investigate the prognostic role of lymphopenia, blood protein levels, and treatment and patient-related factors. MATERIAL AND METHODS: Sixty-two advanced stage non-small cell lung cancer (NSCLC) patients were retrospectively analyzed. Blood counts were available prior to, during, and after RT (3Gyx10). For each patient, a thoracic volume of interest (VOI) –including thoracic soft tissue and trabecular bone– was obtained by applying a CT window of −500 to 1200 HU in the planning CT. Dose parameters from thoracic VOI and other regions including lungs and vertebrae were calculated. Association between risk of lymphopenia ≥ G3 (lymphocytes at nadir according to CTCAE v4.0) and therapeutic parameters was investigated using Logistic regression. Relationships between overall survival (OS) and RT dose parameters, baseline blood counts and protein levels, and clinical factors were evaluated using Log-rank and Cox models. RESULT: Mean thoracic RT dose (odds ratio [OR] 1.67; p = 0.04), baseline lymphocytes (OR 0.65; p = 0.01), and corticosteroids use (OR 6.07; p = 0.02) were significantly associated with increased risk of lymphopenia ≥ G3 in multivariable analysis. Worse OS was associated with high mean thoracic RT dose, high CRP/Albumin, large tumor volume and corticosteroids use (p < 0.05, univariate analysis), but not with lymphopenia ≥ G3. CRP/Albumin ratio > 0.12 (hazard ratio [HR] 2.28, p = 0.03) and corticosteroid use (HR 2.52, p = 0.01) were independently associated with worse OS. CONCLUSION: High thoracic RT dose gave a higher risk of lymphopenia ≥ G3; hence limiting dose volume to the thorax may be valuable in preventing severe lymphopenia for patients receiving palliative fractionated RT. Still, lymphopenia ≥ G3 was not associated with worse OS. however, high baseline CRP/Albumin was associated with poorer OS and may carry important information as a prognostic factor of OS in advanced NSCLC receiving palliative RT. Elsevier 2020-02-19 /pmc/articles/PMC7063172/ /pubmed/32181373 http://dx.doi.org/10.1016/j.ctro.2020.02.005 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abravan, Azadeh
Eide, Hanne Astrid
Helland, Åslaug
Malinen, Eirik
Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
title Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
title_full Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
title_fullStr Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
title_full_unstemmed Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
title_short Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
title_sort radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063172/
https://www.ncbi.nlm.nih.gov/pubmed/32181373
http://dx.doi.org/10.1016/j.ctro.2020.02.005
work_keys_str_mv AT abravanazadeh radiotherapyrelatedlymphopeniainpatientswithadvancednonsmallcelllungcancerreceivingpalliativeradiotherapy
AT eidehanneastrid radiotherapyrelatedlymphopeniainpatientswithadvancednonsmallcelllungcancerreceivingpalliativeradiotherapy
AT hellandaslaug radiotherapyrelatedlymphopeniainpatientswithadvancednonsmallcelllungcancerreceivingpalliativeradiotherapy
AT malineneirik radiotherapyrelatedlymphopeniainpatientswithadvancednonsmallcelllungcancerreceivingpalliativeradiotherapy